Calcified Tissue International

, Volume 73, Issue 4, pp 315–318 | Cite as

Bisphosphonate Actions on Cancer

Review

Abstract

Bisphosphonates (BPs) suppress cancer cell colonization in bone associated with cancers such as breast cancer and multiple myeloma. The mechanism of the suppressive action of BPs is thought to be due to an inhibition of osteoclastic bone resorption which releases bone-stored growth factors that feed cancer cells colonizing bone. Recently, data are accumulating that BP suppresses growth and induces apoptosis in cancer cells in culture, suggesting that BP directly influences survival of cancer cells in an osteoclast-independent manner. These results raise the possibility that BP inhibits cancer growth in organs other than bone. However, evidence is limited that BP reduces tumor growth in non-bone sites in cancer patients. In this review, we discuss the effectiveness of BP on breast cancer colonization in non-bone sites and our results in animal models with metastases. With currently available clinical and in vivo experimental data, BPs are definitely beneficial for the treatment of cancer patients who manifest clinically detectable bone metastases. However, it is not recommended that BP be given as a preventative to patients with visceral metastases and of no evidence of bone metastases. Whether individual BP with different chemical structure has unique biological or biochemical action is an intriguing question but open at the moment.

Keywords

Bisphosphonates Cancer cells 

References

  1. 1.
    Van der Pluijm, G, Vloedgraven, H, van Beek, E, van der Wee-Pals, L, Lowik, C, Papapoulos, S 1996Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.J Clin Invest98698705PubMedGoogle Scholar
  2. 2.
    Boisser, S, Magnetto, S, Frappart, L, Cuzin, B, Ebetino, FH, Delmas, PD, Clezardin, P 1997Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.Cancer Res5738903894PubMedGoogle Scholar
  3. 3.
    Boissier, S, Ferreras, M, Peyruchaud, O, Magnetto, S, Ebetino, FH, Colombel, M, Delmas, P, Delaisse, JM, Clezardin, P 2000Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.Cancer Res6029492954PubMedGoogle Scholar
  4. 4.
    Shipman, CM, Croucher, PI, Russell, RGG, Helfrich, MH, Rogers, MJ 1999The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.Cancer Res5852945297Google Scholar
  5. 5.
    Fromigue, O, Lagneaux, L, Body, JJ 2000Bisphosphonates induce breast cancer cell death in vitro.J Bone Miner Res4522112221Google Scholar
  6. 6.
    Lee, MV, Fong, EM, Singer, FR, Guenette, RS 2001Bisphosphonate treatment inhibits the growth of prostate cancer cells.Cancer Res6126022608PubMedGoogle Scholar
  7. 7.
    Diet, IJ, Solomayer, E-F, Costa, SD, Gollan, C, Goerner, R, Wallwiener, D, Kaufmann, M, Bastert, G 1998Reduction in new metastases in breast cancer with adjuvant clodronate treatment.N Engl J Med339357363Google Scholar
  8. 8.
    Saarto, T, Blomqvist, C, Virkkunen, P, Elomaa, II 2001Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.J Clin Oncol191017PubMedGoogle Scholar
  9. 9.
    Powles, T, Paterson, S, Kanis, JA,  et al. 2002Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.J Clin Oncol2032193224CrossRefPubMedGoogle Scholar
  10. 10.
    Coleman, RE, Rubens, RD 1987The clinical course of bone metastases from breast cancer.Br J Cancer556166PubMedGoogle Scholar
  11. 11.
    Fleisch, H, Reszka, A, Rodan, G, Rogers, M, Bilezikian, JP, Raisz, LG, Rodan, GA 2001

    Mechanism of action.

    Principles of bone biology.Academic PressSan Diego13611385
    Google Scholar
  12. 12.
    Rogers, MJ, Gordon, S, Benford, HL, Coxon, FP, Luckman, SP, Monkkonen, J, Frith, JC 2000Cellular and molecular mechanism of action of bisphosphonates.Cancer8829612978CrossRefPubMedGoogle Scholar
  13. 13.
    Hortobagyi, GN, Theriault, RL, Porter, L, Blayney, D, Lipton, A, Sinoff, C, Wheeler, H, Simeone, JF, Seaman, J, Knight, RD 1996Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases.N Engl J Med33517851791Google Scholar
  14. 14.
    Body, JJ, Bartl, R, Burckhardt, P,  et al. 1998Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.J Clin Oncol1638903899PubMedGoogle Scholar
  15. 15.
    Mundy, GR, Yoneda, T 1998Bisphosphonates as anticancer drugs.N Engl J Med339398400CrossRefPubMedGoogle Scholar
  16. 16.
    Berenson, JR, Hillner, BE, Kyle, RA, Anderson, K, Lipton, A, Yee, GC, Biermann, JS 2002American Society of Clinical Oncology Bisphosphonates Expert Panel American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.J Clin Oncol2037193736CrossRefPubMedGoogle Scholar
  17. 17.
    Sasaki, A, Boyce, BF, Story, B, Wright, KR, Chapman, M, Boyce, R, Mundy, GR, Yoneda, T 1995Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.Cancer Res5535513557PubMedGoogle Scholar
  18. 18.
    Hughes, DE, Wright, KR, Uy, HL, Sasaki, A, Yoneda, T, Roodman, GD, Mundy, GR, Boyce, BF 1995Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.J Bone Miner Res1014781487PubMedGoogle Scholar
  19. 19.
    Hiraga, T, Williams, PJ, Mundy, GR, Yoneda, T 2201The bisphosphonate ibandronate promotes apoptosis in MDA-231 human breast cancer cells in bone metastases.Cancer Res6144184424Google Scholar
  20. 20.
    Sato, M, Grasser, W, Endo, N, Akins, R, Simmons, H, Thompson, DD, Golub, E, Rodan, GA 1991Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.J Clin Invest8820952105PubMedGoogle Scholar
  21. 21.
    Diel IJ, Solomayer E-F, Gollan C, Shutz F, Bastert G (2000) Bisphosphonates in the reduction of metastases in breast cancer: results of the extended follow-up of the first study population (abstract 314). Proceedings ASCOGoogle Scholar
  22. 22.
    Kostenuik, PJ, Orr, FW, Suyama, K, Orr, FW 1993Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats.Cancer Res5354525457Google Scholar
  23. 23.
    Stearns, ME, Wang, M 1996Effects of alendronate and taxol on PC-3ML cell bone metastases in SCID mice.Invasion Metastasis16116131PubMedGoogle Scholar
  24. 24.
    Michigami, T, Hiraga, T, Williams, PJ, Nishimura, R, Mundy, GR, Yoneda, T 2002The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.Breast Cancer Res Treat75249258CrossRefPubMedGoogle Scholar
  25. 25.
    Yoneda, T, Michigami, T, Yi, B, Williams, PJ, Niewolna, M, Hiraga, T 2000Action of bisphosphonate on bone metastasis in animal models of breast carcinoma.Cancer8829792988CrossRefPubMedGoogle Scholar
  26. 26.
    Hillner, BE, Ingle, JN, Berenson, JR, Janjan, NA, Albain, KS, Lipton, A, Yee, G, Biermann, JS, Chlebowski, RT, Pfister, DG 2000American society of clinical oncology guideline on the role of bisphosphonates in breast cancer.J Clin Oncol1813781391PubMedGoogle Scholar
  27. 27.
    Sawada, K, Morishige, K, Tahara, M, Kawagishi, R, Ikebuchi, Y, Tasaka, K, Murata, Y 2002Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho.Cancer Res6260156020PubMedGoogle Scholar
  28. 28.
    Green, JR, Muller, K, Jaeggi, KA 1994Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound.J Bone Miner Res9745751PubMedGoogle Scholar
  29. 29.
    Fournier, P, Boissier, S, Filleur, S, Guglielmi, J, Cabon, F, Colombel, M, Clezardin, P 2002Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.Cancer Res6265386544PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Department of Biochemistry, Department of MedicineOsaka University Graduate School of Dentistry, Japan and Endocrine Research, The University of Texas Health Science Center at San Antonio, TexasUSA

Personalised recommendations